Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in adult participants with MOGAD
NCT05063162Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Feb 2022
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of rozanolixizumab in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), sponsored by UCB. Started Feb 2022; status: active, not recruiting.
02
Drugs
rozanolixizumab
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on NCT05063162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063162.